Abstracts tagged "immune response and vasculitis"

Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting
TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Peadar Rooney¹, Danielle Molloy¹, Jennifer McCormick², Mary Connolly¹, Sinead M. Miggin³, Ashwini Maratha³, Douglas J. Veale⁴, Conor Murphy⁵, Eamonn Molloy⁶ and Ursula Fearon⁷, ¹Rheumatology, Dublin Academic Medical Centre, Dublin, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Biology, Immune Signalling Laboratory, Maynooth, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁷Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].